• 1
    De Koning HJ,Auvinen A,Berenguer SA,Calais dS,Ciatto S,Denis L,Gohagan JK,Hakama M,Hugosson J,Kranse R,Nelen V,Prorok PC, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97: 23744.
  • 2
    Gohagan JK,Prorok PC,Kramer BS,Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the national cancer institute. J Urol 1994; 152: 19059.
  • 3
    Andriole GL,Levin DL,Crawford ED,Gelmann EP,Pinsky PF,Chia D,Kramer BS,Reding D,Church TR,Grubb RL,Izmirlian G,Ragard LR, et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) Cancer. screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 4338.
  • 4
    Schroder FH,Denis LJ,Roobol M,Nelen V,Auvinen A,Tammela T,Villers A,Rebillard X,Ciatto S,Zappa M,Berenguer A,Paez A, etal. The story of the European randomized study of screening for prostate cancer. BJU Int 2003; 92( Suppl 2): 113.
  • 5
    De Koning HJ,Liem MK,Baan CA,Boer R,Schroder FH,Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial. Int J Cancer 2002; 98: 26873.
  • 6
    Swan J,Breen N,Coates RJ,Rimer BK,Lee NC. Progress in cancer screening practices in the United States: results from the 2000 national health interview survey. Cancer 2003; 97: 152840.
  • 7
    Melia J,Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001; 85: 6567.
  • 8
    Oliver SE,May MT,Gunnell D. International trends in prostate-cancer mortality in the “PSA ERA”. Int J Cancer 2001; 92: 8938.
  • 9
    CuradoMP,EdwardsB,ShinHR,StormH,FerlayJ,HeanueM,BoyleP, eds.Cancer incidence in five continents, vol. 9. Lyon: IARC, 2007. IARC Scientific Publications No. 160.
  • 10
    Berrino F,De Angelis R,Sant M,Rosso S,Bielska-Lasota M,Coebergh JW,Santaquilani M; EUROCARE working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773–83. Erratum in: Lancet Oncol 2007 Oct;8:868. Lasota, Magdalena B [corrected to Bielska-Lasota, Magdalena]. PMID: 17714991.
  • 11
    Vutuc C,Waldhoer T,Madersbacher S,Micksche M,Haidinger G. Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. Eur J Cancer Prev 2001; 10: 4258.
  • 12
    Sarma AV,Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981–2001. Semin Urol Oncol 2002; 20: 39.
  • 13
    Quinn M,Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90: 16273.
  • 14
    Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29: 17381.
  • 15
    Chu KC,Tarone RE,Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 2003; 97: 150716.
  • 16
    Evans HS,Moller H. Recent trends in prostate cancer incidence and mortality in Southeast England. Eur Urol 2003; 43: 33741.
  • 17
    McDavid K,Lee J,Fulton JP,Tonita J,Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004; 119: 17486.
  • 18
    Levi F,Lucchini F,Negri E,Boyle P,La Vecchia C. Leveling of prostate cancer mortality in Western Europe. Prostate 2004; 60: 4652.
  • 19
    Horninger W,Berger A,Pelzer A,Klocker H,Oberaigner W,Schonitzer D,Severi G,Robertson C,Boyle P,Bartsch G. Screening for prostate cancer: updated experience from the Tyrol study. Can J Urol 2005; 12( Suppl 1): 713.
  • 20
    Oberaigner W,Horninger W,Klocker H,Schonitzer D,Stuhlinger W,Bartsch G. Reduction of prostate cancer mortality in Tyrol. Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 2006; 164: 37684.
  • 21
    Quaglia A,Parodi S,Grosclaude P,Martinez-Garcia C,Coebergh JW,Vercelli M. Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe. An analysis of differential trends in incidence and mortality in France, Italy and Spain. Eur J Cancer 2003; 39: 65465.
  • 22
    Stracci F,Canosa A,Minelli L,Petrinelli AM,Cassetti T,Romagnoli C,La Rosa F. Cancer mortality trends in the Umbria region of Italy 1978–2004: a joinpoint regression analysis. BMC Cancer 2007; 7: 10.
  • 23
    Baade PD,Coory MD,Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 2004; 15: 23741.
  • 24
    International Agency for Research on Cancer (IARC). CancerMondial. Access date February 2007.
  • 25
    National Cancer Institute, National cancer insti. Statistical research and applications. Joinpoint Regression Program.
  • 26
    Feuer EJ,Merrill RM,Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer–part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 102532.
  • 27
    Coldman AJ,Phillips N,Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003; 168: 315.
  • 28
    Bouchardy C,Boggio P,Rapin CH,Deom A,Iselin C. [Prostate cancer screening in Geneva: a physician survey]. Le dépistage du cancer de la prostate à Genève: une étude auprès des médecins traitants. Bull. Suisse. Cancer 2004; 2400: 914.
  • 29
    Vincendeau S,Abi MM,Manunta A,Patard JJ,Guille F,Lobel B. [PSA: the difficult position of general practitioners between patients and urologists]. Prog Urol 2003; 13: 2525.
  • 30
    Menegoz F,Colonna M,Exbrayat C,Mousseau M,Orfeuvre H,Schaerer R. A recent increase in the incidence of prostatic carcinoma in a French population: role of ultrasonography and prostatic specific antigen. Eur J Cancer 1995; 31A: 558.
  • 31
    Skovlund E,Fossa SD. [PSA analyses in three Norwegian counties in 1999]. Tidsskr Nor Laegeforen 2000; 120: 253941.
  • 32
    Beemsterboer PM,De Koning HJ,Kranse R,Trienekens PH,Van der Maas PJ,Schroder FH. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer. Rotterdam. J Urol 2000; 164: 121620.
  • 33
    Jonler M,Eddy B,Poulsen J. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Scand J Urol Nephrol 2005; 39: 2148.
  • 34
    Etzioni R,Penson DF,Legler JM,di Tommaso D,Boer R,Gann PH,Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 98190.
  • 35
    IARC Handbook of cancer prevention n. 10, Cervix Cancer Screening. IARC, Lyon 2005.
  • 36
    Hoffman RM,Stone SN,Hunt WC,Key CR,Gilliland FD. Effects of misattribution in assigning cause of death on prostate cancer mortality rates. Ann Epidemiol 2003; 13: 4504.
  • 37
    Lu-Yao G,Stukel TA,Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004; 171: 228590.
  • 38
    Viville C. Total prostatectomy for cancer. Mortality and morbidity. Apropos of 1288 operations. The ANFUC survey. J Urol (Paris) 1994; 100: 37.
  • 39
    Huland H. The risk outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against. Eur Urol 1996; 29( Suppl 2): 313.
  • 40
    Gilliland F,Becker TM,Smith A,Key CR,Samet JM. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev 1994; 3: 10511.
  • 41
    Mettlin C. Impact of screening on prostate cancer rates and trends. Microsc Res Tech 2000; 51: 4158.
  • 42
    Hankey BF,Feuer EJ,Clegg LX,Hayes RB,Legler JM,Prorok PC,Ries LA,Merrill RM,Kaplan RS. Cancer surveillance series: interpreting trends in prostate cancer–part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 101724.
  • 43
    Feuer EJ,Mariotto A,Merrill R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer 2002; 95: 87080.
  • 44
    Roberts RO,Bergstralh EJ,Katusic SK,Lieber MM,Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted county, Minnesota. J Urol 1999; 161: 52933.
  • 45
    Vis AN. Does PSA screening reduce prostate cancer mortality? CMAJ 2002; 166: 6001.
  • 46
    Etzioni R,Legler JM,Feuer EJ,Merrill RM,Cronin KA,Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer. III. quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 10339.